Telomir Pharmaceuticals (NASDAQ: TELO) has announced the peer-reviewed publication of preclinical data in Biomedicine & Pharmacotherapy showing that its lead candidate, Telomir-Zn, restored insulin sensitivity and improved glucose homeostasis in a diet-induced zebrafish model of Type 2 diabetes. According to the study, treatment with Telomir-Zn produced dose-dependent reductions in fasting blood glucose and insulin levels, improved glucose tolerance, and significantly lowered HOMA-IR scores, a widely used measure of insulin resistance.
The findings add to a growing body of evidence supporting Telomir-Zn’s mechanism of action through modulation of intracellular metal homeostasis. The company noted that the biological pathways targeted by Telomir-Zn have been implicated in both metabolic disease and cancer. The results complement the company’s recently FDA-cleared Phase 1/2 clinical program evaluating the drug in patients with advanced or metastatic triple-negative breast cancer.
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. The company’s lead program, Telomir-1 (Telomir-Zn), has demonstrated activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability.
The full press release is available at https://ibn.fm/BoK2F. For more information about Telomir Pharmaceuticals, visit the company’s newsroom at https://ibn.fm/TELO.
